Updates on the Management of Motor Signs and Symptoms of Parkinson’s Disease

Tuesday, April 7, 2020, 8:00 AM - Wednesday, April 7, 2021, 11:59 PM

AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

This activity offers a unique approach to digital case-based, patient-centric education in which learners are challenged to consider the care delivered in a clinical scenario and recognize potential sub-optimal treatment approaches or management strategies implemented by the healthcare team. Learners will identify changes to the described care that could improve patient outcomes, such as treatment selection for PD motor symptoms or integration of shared decision-making (SDM). These issues will be fully examined by the faculty through commentary and discussions. Learners will then have the opportunity to apply key learning by managing a similar, but different, clinical scenario.

There are no fees for participating in and receiving CME credit for this online activity.

Click here, to access this activity.

1. Review the efficacy and safety of agents for the management of early motor symptoms of PD;
2. Outline pharmacologic options for managing motor fluctuations in PD;
3. Describe factors that should be considered when using an on-demand management plan for late motor symptoms.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The University of Cincinnati and Clinical Care Options are accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for activity.

Faculty & Disclosure / Conflict of Interest Policy

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity.  All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Staff Disclosures
The University of Cincinnati and Clinical Care Options, LLC, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor Clinical Care Options, LLC., recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement
The opinions expressed during this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

 This educational activity is supported by an educational grant from Acorda Therapeutics, Inc. and Sunovion Pharmaceuticals, Inc.